

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Zhang Jack Y.</u> (Last) (First) (Middle) C/O AMPHASTAR PHARMACEUTICALS, INC. 11570 6TH STREET (Street) RANCHO CA 91730 CUCAMONGA (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>Amphastar Pharmaceuticals, Inc. [AMPH]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director <input checked="" type="checkbox"/> 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <u>CEO & Chief Scientific Officer</u>
	3. Date of Earliest Transaction (Month/Day/Year) <u>03/15/2019</u>	
4. If Amendment, Date of Original Filed (Month/Day/Year)		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	03/15/2019		M		514,783	A	\$15.84	2,587,100	D	
Common Stock	03/15/2019		F		461,097 ⁽¹⁾	D	\$20.23	2,126,003	D	
Common Stock	03/15/2019		A		98,368 ⁽²⁾	A	\$0	2,224,371	D	
Common Stock	03/15/2019		F		17,205 ⁽³⁾	D	\$20.23	2,207,166	D	
Common Stock	03/16/2019		F		27,476 ⁽³⁾	D	\$20.23	2,179,690	D	
Common Stock	03/17/2019		F		32,374 ⁽³⁾	D	\$20.23	2,147,316	D	
Common Stock	03/15/2019		M		224,737	A	\$15.84	1,591,443	I	See footnote ⁽⁴⁾
Common Stock	03/15/2019		F		200,853 ⁽¹⁾	D	\$20.23	1,390,590	I	See footnote ⁽⁴⁾
Common Stock	03/15/2019		A		41,522 ⁽²⁾	A	\$0	1,432,112	I	See footnote ⁽⁴⁾
Common Stock	03/15/2019		F		7,317 ⁽³⁾	D	\$20.23	1,424,795	I	See footnote ⁽⁴⁾
Common Stock	03/16/2019		F		11,832 ⁽³⁾	D	\$20.23	1,412,963	I	See footnote ⁽⁴⁾
Common Stock	03/17/2019		F		13,941 ⁽³⁾	D	\$20.23	1,399,022	I	See footnote ⁽⁴⁾
Common Stock								7,327,679	I	See footnote ⁽⁵⁾
Common Stock								5,000	I	See footnote ⁽⁶⁾
Common Stock								200,000	I	See footnote ⁽⁷⁾

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Employee Stock Option (right to buy)	\$15.84	03/15/2019		M			514,783	(8)	03/27/2019	Common Stock	0	\$0	0	D	
Employee Stock Option (right to buy)	\$22.25	03/15/2019		A		262,182		(9)	03/15/2027	Common Stock	262,182	\$0	262,182	D	
Employee Stock Option (right to buy)	\$15.84	03/15/2019		M			224,737	(8)	03/27/2019	Common Stock	0	\$0	0	I	See footnote ⁽⁴⁾
Employee Stock Option (right to buy)	\$22.25	03/15/2019		A		110,671		(9)	03/15/2027	Common Stock	110,671	\$0	110,671	I	See footnote ⁽⁴⁾

1. Name and Address of Reporting Person*

Zhang Jack Y.

(Last) (First) (Middle)

C/O AMPHASTAR PHARMACEUTICALS, INC.
11570 6TH STREET

(Street)

RANCHO CA 91730
CUCAMONGA

(City) (State) (Zip)

1. Name and Address of Reporting Person*

Luo Mary Z.

(Last) (First) (Middle)

C/O AMPHASTAR PHARMACEUTICALS, INC.
11570 6TH STREET

(Street)

RANCHO CA 91730
CUCAMONGA

(City) (State) (Zip)

Explanation of Responses:

- The reported shares were withheld to satisfy the reporting person's tax liability in connection with the option exercise.
- The reported shares are represented by restricted stock units, or RSUs, which vest in three equal annual installments beginning on March 15, 2020.
- The reported shares were withheld to satisfy the reporting person's tax liability in connection with the vesting of RSUs.
- The securities are held of record by Mary Z. Luo. The reporting persons are husband and wife.
- The shares are held of record by Applied Physics & Chemistry Laboratories, Inc., of which the reporting persons and The Bill Luobei Zhang 2004 Irrevocable Trust (the "BLZ Trust") are the sole owners.
- The shares are held of record in an account for the benefit of the reporting persons' son. The reporting persons disclaim beneficial ownership of these shares, and the inclusion of these shares in this report should not be deemed an admission of beneficial ownership of any such shares for purposes of Section 16, or for any other purpose.
- The shares are held of record by the BLZ Trust. The reporting persons disclaim beneficial ownership of these shares, and the inclusion of these shares in this report should not be deemed an admission of beneficial ownership of any such shares for purposes of Section 16, or for any other purpose.
- Shares subject to the option are fully vested and immediately exercisable.
- Shares subject to the option vest in three equal annual installments beginning on March 15, 2020.

/s/ Eva Wen, by power of attorney for Jack Y. Zhang 03/18/2019

/s/ Eva Wen, by power of attorney for Mary Z. Luo 03/18/2019

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.